Application of [(3-aminopyridine-2-yl) methylene amino]-2-nitrobenzoate in preparation of influenza virus inhibition product

By using [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate small molecule compound, the problem of anti-influenza drug resistance in the prior art was solved, and the method was achieved The efficient inhibition of influenza viruses and the promotion of cell autophagy provide a novel method to treat or prevent influenza A virus infection.

CN119015280AActive Publication Date: 2024-11-26XINXIANG MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411176772.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-26
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

There has been no reported effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the prior art, resulting in anti-influenza drugs facing drug resistance and lack of effectiveness. new anti-influenza virus drug.

Method used

[(3-aminopyridin-2-yl)methylene amino]-2-nitrobenzoate was used as a small molecule compound. Through experimental studies, it was found that it had a significant inhibitory effect on influenza A virus at the cellular level. Preparation It is used to treat or prevent influenza A virus infection.

Benefits of technology

On the basis of not affecting cell activity, [(3-aminopyridin-2-yl)methylene amino]-2-nitrobenzoate inhibits influenza A virus by 95%, with a relatively large Clinical application potential and show low cytotoxicity and efficient anti-influenza properties, while also having the effect of promoting autophagy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015280A_ABST
    Figure CN119015280A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological agents, and particularly relates to application of [(3-aminopyridine-2-yl) methylene amino]-2-nitrobenzoate in preparation of products for inhibiting influenza viruses. It is found for the first time that [(3-aminopyridine-2-yl) methylene amino]-2-nitrobenzoate has a remarkable inhibition effect on influenza A viruses at the cellular level, and the efficiency of inhibiting the influenza A viruses reaches 95% on the basis that cell activity is not affected, so that the [(3-aminopyridine-2-yl) methylene amino]-2-nitrobenzoate has great clinical application potential.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological preparations, and specifically relates to the application of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of a product for inhibiting influenza virus. Background Art

[0002] Autophagy is involved in almost all basic cell activities and is closely related to the occurrence and development of many human diseases. Studies have shown that autophagy is closely related to viral infection. Autophagy is an intracellular self-digestion process that maintains cell homeostasis by degrading intracellular substances. In the case of viral infection, autophagy plays a dual role: on the one hand, it is a defense mechanism of host cells that limits viral replication by removing virally infected cell components; on the other hand, viruses also use autophagy to promote their own replication and survival. Autophagy as a host defense mechanism: During viral infection, host cells will initiate autophagy to remove virally infected cell components, thereby limiting viral replication. For example, Streptococcus pyogenes will be isolated by autophagosomes during infection and eventually degraded in lysosomes. In addition, interferon can upregulate autophagy levels, further enhancing the antiviral ability of host cells. Viruses use autophagy to promote their own replication: Some viruses also use autophagy to promote their own replication. For example, influenza virus nucleoprotein NP can also induce mitochondrial autophagy and promote viral replication, which is a strategy for viruses to hijack the host metabolic system to maintain their own replication.

[0003] In summary, autophagy is closely related to viral infection, serving as a defense mechanism for the host and being used by the virus to promote its own survival and replication. This interaction reflects the complex interaction between cells and viruses, which is of great significance for understanding the mechanism of viral infection and developing effective antiviral strategies.

[0004] Influenza virus is called influenza virus for short. According to the difference of influenza virus nucleoprotein NP and matrix protein M, it can be divided into four types: A (A), B (B), C (C) and D (D). Influenza A and B viruses can cause outbreaks and epidemics, while influenza C virus causes mild infection. Only influenza A virus (IAV) can cause a global pandemic. Every year, IAV causes about 290,000 to 650,000 deaths worldwide and is listed by WHO as one of the top ten threats to global health.

[0005] IAV has a segmented negative-sense single-stranded RNA genome and exhibits a wide host range. This allows IAV to circulate continuously in nature and produce genetically diverse variants through evolution. These mutations can lead to seasonal epidemics, unpredictable pandemics, and outbreaks of zoonotic diseases. The extremely high gene recombination efficiency of IAV seriously affects the effectiveness of influenza vaccines, and anti-influenza drugs have become the key to clinical treatment. At present, the drugs for the treatment of influenza mainly use some neuraminidase inhibitors and ion channel M2 protein inhibitors. However, with the mutation of the virus, the existing anti-influenza drugs face severe drug resistance. Widespread antiviral resistance limits the clinical application of these inhibitors in the prevention and treatment of influenza infections. Therefore, in order to meet the urgent needs of clinical influenza patients for treatment, the development of new anti-influenza virus drugs is imminent.

[0006] The molecular formula of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is C 13 H 10 N4O4, with a molecular weight of 286.247, is composed of the functional groups amino(pyridin-2-yl)methylidene and amino2-nitrobenzoate. So far, there has been no report on the inhibitory effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on influenza virus. Summary of the invention

[0007] In order to solve the problem that there is no report on the inhibitory effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on influenza virus in the prior art, the present invention provides an application of a small molecule compound [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of a product for inhibiting influenza virus.

[0008] To achieve the above object, the present invention adopts the following technical solution:

[0009] The present invention provides the use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of a product for inhibiting influenza virus, wherein the influenza virus is influenza A virus; the influenza A virus includes the H1N1 (A / PR / 8 / 34) strain.

[0010] Among them, the products include reagents used for laboratory research on influenza viruses or other products that inhibit influenza viruses.

[0011] The present invention also provides the use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in preparing a drug for treating or preventing influenza A virus infection, and the use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in preparing an anti-influenza A virus drug.

[0012] The present invention also provides the use of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of a drug for promoting cell autophagy.

[0013] Among them, the molecular formula of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is C 13 H 10 N4O4, molecular weight is 286.247, structural formula is as follows:

[0014]

[0015] Among them, the English name of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is [amino(pyridin-2-yl)methylidene]amino 2-nitrobenzoate.

[0016] The present invention has found through research that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate has a significant inhibitory effect on influenza A virus at the cellular level, and the efficiency of inhibiting influenza A virus reaches 95% without affecting cell activity, which makes it have great clinical application potential. Therefore, the present invention provides an effective small molecule compound for the treatment of influenza A virus in clinical practice.

[0017] Preferably, the drug contains the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate as an active ingredient and is supplemented with a pharmaceutically acceptable carrier.

[0018] Preferably, the carrier comprises any one or more of glycerol, lecithin and cholesterol.

[0019] Preferably, the effective concentration of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the drug is 10 μM to 40 μM.

[0020] Preferably, the medicine includes oral dosage forms, injection dosage forms and inhalation dosage forms.

[0021] Among them, the oral dosage form is to form [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate with auxiliary materials into a solid or liquid preparation and then take it orally, which is convenient to carry and take.

[0022] The injection dosage forms include normal saline injection and sterile injection of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate powder, which are rapidly absorbed and effective.

[0023] The inhalation dosage form is to encapsulate [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate and its solution with a suitable propellant in a pressure-resistant closed container with a special valve system. When used, the content is sprayed out in a mist with the help of the pressure of the propellant. The drug onset time is faster than that of oral drugs, and the side effects are relatively less. The present invention can prepare [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate into the following specific pharmaceutical dosage forms, but is not limited thereto. As long as [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is prepared through the field of pharmaceutical preparations, the pharmaceutical dosage form that can be used for the prevention and treatment of rheumatoid arthritis can be used.

[0024] Preferably, the drug is in the form of a solution, tablet or granule.

[0025] According to the actual treatment purpose and treatment plan, [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate can be prepared into different types of drugs to achieve the effect of preventing and treating influenza A virus infection.

[0026] Preferably, the drug is a solution. The drug in a solution has a large dispersion, fast absorption, rapid action, and good bioavailability; the active ingredients are evenly dispersed and can be accurately measured and used, which is especially suitable for children and elderly patients; the dosage size is easy to adjust and control; it can reduce the local irritation of certain soluble drugs; and it can increase the stability and safety of certain drugs. Therefore, the dosage form of the above-mentioned drug provided by the present invention is a solution.

[0027] The solvent in the solution is DMSO; the effective concentration of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the drug is 10 μM to 40 μM.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] 1. The present invention provides the use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in products for inhibiting influenza virus. The research results of the present invention prove that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate has a significant inhibitory effect on influenza A virus at the cellular level, and the efficiency of inhibiting influenza A virus reaches 95% without affecting cell activity, which makes it have great clinical application potential. Through this new discovery, a drug for treating or preventing influenza A virus infection is developed.

[0030] [(3-Aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is a small molecule compound with little toxicity to A549 cells. When the concentration is 40 μM, the cell survival rate is above 80%, indicating that it is safe and has low cytotoxicity.

[0031] When [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate acts on A549 cells at a concentration of 40 μM, the inhibition rate of viral nucleic acid copy number of influenza A virus H1N1 (PR8) replication reaches more than 99%, indicating that it has high anti-influenza properties.

[0032] 2. The present invention also found through research that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate has the effect of promoting cell autophagy and can be used to prepare drugs that promote cell autophagy, and is expected to play an important role in tumor treatment, viral infection, obesity, diabetes and other diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Schematic diagram of the cytotoxicity of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on A549 cells in the present invention.

[0034] Figure 2 Schematic diagram of Western Blot detection effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate against influenza A virus at the cellular level in the present invention; wherein, Figure 2 A in the figure is a Western Blot showing the effect of different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of influenza A virus at the cellular level. The weaker the band, the lower the virus content. GADPH is the cell internal reference control. The lanes from left to right represent the working concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate as 0μM, 10μM, 20μM, and 40μM, respectively. Figure 2 B in the figure is the ratio of the gray value of the influenza A (H1N1) virus nucleoprotein (NP) band to the gray value of the cell internal reference (GADPH) band. The smaller the ratio, the lower the virus content. The horizontal axis values ​​from left to right represent the working concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate as 0 μM, 20 μM, 30 μM, and 40 μM, respectively.

[0035] Figure 3 The figure is a schematic diagram of the Western Blots detection results of the inhibitory effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on influenza A virus at different time points at the cellular level in the present invention; wherein. Figure 3A in the figure is the result of Western Blots, showing the effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate at a concentration of 40 μM on the proliferation of influenza A virus at different time points. The weaker the band, the lower the virus content. GADPH is the cell internal reference control. The lanes from left to right represent 12 hours, 24 hours and 36 hours of PR8 influenza virus infection, respectively. Figure 3 B in the figure is the ratio of the gray value of the influenza A (H1N1) virus nucleoprotein (NP) band to the gray value of the cell internal reference (GADPH) band. The smaller the ratio, the lower the virus content.

[0036] Figure 4 Schematic diagram of Western Blots detection results of different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate at the cellular level in the present invention promoting the degradation of autophagy marker protein p62, wherein: Figure 4 A in the figure is the result of Western Blots, showing the effect of different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the autophagy marker protein p62 after 24 hours of treatment. The weaker the band, the stronger the promotion of autophagy. GADPH is the cell internal reference control. The lanes from left to right represent the concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate of 0, 10, 20, and 40 μM, respectively; Figure 4 B in the figure is the ratio of the grayscale value of the autophagy marker protein (p62) and the cell internal reference (GADPH). The smaller the ratio, the stronger the degree of autophagy.

[0037] Figure 5 Schematic diagram of the promotion of GFP-LC3 spot formation by [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate at a concentration of 40 μM in the present invention, wherein: Figure 5 A in the figure is a related picture taken under a laser confocal microscope; Figure 5 B in the figure is the statistical result of the number of GF-LC3 spots formed in each cell. The greater the number, the stronger the degree of promoting autophagy. DETAILED DESCRIPTION

[0038] The present invention will be described in detail below in conjunction with the accompanying drawings and specific examples, but they should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0039] At present, antiviral drug evaluation models are mainly divided into in vitro models and in vivo models.

[0040] Among them, the in vitro model mainly uses various cell lines to evaluate drugs. Its advantages are that it can provide a large number of cells with the same genetic characteristics as research objects, it is easy to operate, can eliminate the influence of other external factors, and can detect drug toxicity, effective concentration, etc., providing more basis for later mechanism research.

[0041] The advantage of in vivo models is that they allow for a true and systematic evaluation of the effects of candidate drugs in vivo.

[0042] The antiviral drug evaluation model used in the present invention is an in vitro model, specifically, the human non-small cell lung cancer cell line A549 is used to evaluate the in vitro anti-influenza A virus effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate.

[0043] The experimental materials used in the following examples are as follows:

[0044] (1) Cell lines, experimental animals and viruses required for the experiment

[0045] Cell line: Human non-small cell lung cancer cell line A549 is preserved by the Henan Provincial Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical College. Human non-small cell lung cancer cell line A549 is also called A549 cells.

[0046] Jurkat cells were obtained from ATCC.

[0047] Strain: The influenza A virus H1N1 (A / PR / 8 / 34 strain) model virus was preserved by the Immunology Research Center of Xinxiang Medical College.

[0048] (2) Drugs required for the experiment.

[0049] [(3-Aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate was purchased from Shanghai Taoshu Biotechnology Co., Ltd.

[0050] In the actual cell test in the example, [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate was dissolved in DMSO to prepare a [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate solution, which was then diluted to a working concentration with DMEM / F12 culture medium to obtain [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solutions of different concentrations for use in the test.

[0051] Wherein, DMEM / F12 medium is a serum-free basal medium purchased from GIBCO.

[0052] (3) Reagents required for the experiment:

[0053] DMEM / F12 culture medium and fetal bovine serum (FBS) were purchased from GIBCO.

[0054] Cell activity detection kit: TransDetect Cell Counting Kit (CCK) was purchased from Beijing Quanshijin Biotechnology.

[0055] Example 1: Toxicity test of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on cells

[0056] A549 cells were used in the present invention, and a 96-well plate was inoculated. When the cell density reached 80%, the cells were incubated for 48 hours with a final concentration of 0 μM, 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate solution. After the incubation, the cell activity was determined using a TransDetect cell counting kit, and the OD was determined according to the instructions of the kit. 450nm The specific implementation process is as follows:

[0057] 1. Cell culture

[0058] The A549 cells that were revived from cryopreservation were passaged twice and then expanded and cultured in DMEM / F12 medium containing 10% fetal bovine serum and double antibodies.

[0059] Among them, the dual antibiotics are penicillin 100U / mL and streptomycin 100ug / mL.

[0060] 2. Toxicity test of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on cells

[0061] Take well-growing A549 cells for digestion and subculture, and adjust the cell density to 2×10 6 / mL, inoculate it into a 96-well plate, with 100 μL in each well; then add 100 μL of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution prepared with culture medium into each well and mix well.

[0062] The above-mentioned [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution was set to 6 concentration gradients, and each gradient concentration was set to 3 replicates, and the final concentrations were 0μM, 10μM, 20μM, 40μM, 80μM, and 160μM, respectively. At the same time, a cell control was set up and placed in a 37°C, 5% CO2 incubator for culture. After 48 hours of culture, the cell activity was determined using the TransDetect cell counting box, and 10μL of CCK-8 reagent was added to the 96-well plate cells after treatment and culture, and incubated at 37°C in the dark for 2 hours, and the OD was detected by an enzyme marker. 450nm Read the count and calculate the cell viability.

[0063] The cell growth medium is DMEM / F12 culture medium + 10% fetal bovine serum + double antibody.

[0064] The culture medium is DMEM / F12 medium + 10% serum + double antibody.

[0065] Cell survival rate (%) = OD of drug-treated group 450nm / untreated control group OD 450nm *100%

[0066] Test results:

[0067] The results are as follows Figure 1 As shown in Table 1, the determination of cell viability can reflect the toxic effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on A549 cells.

[0068] Table 1 Effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on cell activity

[0069]

[0070]

[0071] from Figure 1 As can be seen from Table 1, after A549 cells were treated with [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate at a concentration of 40 μM for 48 h, the cell viability was maintained at 83.7% compared with the control group, indicating that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate had low cytotoxicity at this concentration.

[0072] Example 2: Inhibitory effect of different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on influenza A virus at the cellular level

[0073] The present invention uses Western Blots and the number of viral nucleic acid copies in the culture supernatant to detect the effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of influenza A virus (PR8) at the cellular level, and the specific steps are as follows:

[0074] 1. Cells were treated with different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate and infected with influenza A virus (PR8)

[0075] 1) Digest and subculture A549 cells with good growth status, and adjust the cell density to 1×10 5 / mL, 1mL per well was inoculated in a 12-well plate to grow into a monolayer.

[0076] 2) Add different amounts of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution, and the final concentrations are 0 μM, 10 μM, 20 μM, and 40 μM, respectively. Among them, the 0 μM working concentration is the DMSO control.

[0077] 3) After being treated with different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution for 24 h, the cells were infected with PR8 influenza virus, and the cells were incubated for 1 h at MOI = 0.05. The virus solution was discarded and the cells were continued to be cultured with the above-mentioned DMEM / F12 cell growth medium containing different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate.

[0078] 4) 24 hours after virus infection, the supernatant and cell lysate were collected, and the influenza virus NP protein in the lysate was detected by Western Blots. The viral nucleic acid copies in the supernatant were detected by fluorescent quantitative PCR to reflect the inhibition of the drug on the virus.

[0079] 2. Western Blots were used to detect the proliferation of influenza A virus PR8 on cells under the action of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate.

[0080] The cell lysate infected with influenza virus was subjected to Western Blots experiment to detect the effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of influenza A virus PR8. The specific steps are as follows:

[0081] Add 5x protein loading to the virus-infected cell lysate collected above, boil in boiling water for 10 minutes, and centrifuge briefly for use.

[0082] SDS-PAGE electrophoresis: prepare separation gel as 10% polyamide gel by volume, spot electrophoresis, constant voltage 80V for 30min for concentrated gel, constant voltage 120V for 1.5h for separation gel.

[0083] Transfer: When transferring, pre-cool the transfer solution in advance, put the PAGE gel after electrophoresis into the transfer tank, and transfer the membrane at a constant voltage of 100V for 1 hour.

[0084] Blocking: After transfer, take out the NC membrane and block it with blocking solution for 1 hour.

[0085] After the primary and secondary antibody incubation is completed, color development is performed: Thermo's ECL color development kit is used for color development.

[0086] 3. Determination of viral nucleic acid copy number in influenza A virus proliferation fluid by fluorescence quantitative PCR

[0087] The amount of virus in the culture supernatant after the above-mentioned influenza virus infection is reflected by detecting the number of copies of the NP gene of the influenza virus. The specific operation method is: 100 μL of the culture supernatant after the virus infected A549 cells was aspirated, and the viral nucleic acid in the culture supernatant after the virus infected A549 cells was extracted using the virus nucleic acid extraction kit (R4171-02) of Magen. The standard curve of the influenza virus NP plasmid was set by fluorescent quantitative PCR, and the NP nucleic acid level of the influenza virus in the supernatant was calculated according to the Ct value of the fluorescent quantitative PCR test result.

[0088] Among them, the steps of fluorescence quantitative PCR detection are reverse transcription first, and then fluorescence quantitative amplification, as shown in detail as follows:

[0089] The extracted RNA was subjected to reverse transcription in 40 μL of the following reaction system: 1.0 μL of AMV reverse transcriptase, 8.0 μL of 5×AMVBuffer, 0.5 μL of RNase inhibitor, 2.5 μL of 10 pmol of Oligo d(T)18, 1 μg of RNA template, 2.5 μL of dNTP (10 mM), 40 μL of ddH2O, gently mixed, and placed on a PCR instrument for reverse transcription: 42°C, 60 min; 72°C, 15 min; 4°C storage. The reaction product was used directly or stored at -20°C for later use.

[0090] The fluorescence quantitative PCR system was as follows: 5 μL 2×SYBR Green MasterMix (Rox), 1 μL cDNA, 0.25 μL of each of the upstream and downstream primers at 10 mM, and finally 3.5 μL of DEPC-treated water was added to a total volume of 10 μL. The reaction conditions were as follows: hot start at 95°C for 15 seconds; then denaturation at 95°C for 5 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds, for a total of 40 cycles; melting curve amplification. Three replicates were set for each sample, and the transcription level of each gene was averaged with the internal reference GAPDH and was calculated by 2 -△△Ct Calculated by formula.

[0091] Test results:

[0092] The results are as follows Figure 2 Western Blots results show that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate significantly inhibited the replication of PR8 influenza virus. After virus infection, the gray value of viral NP protein in the cell fluid treated with 40μM concentration of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate was significantly lower than that in the control group without drug addition, and Figure 2 It can be seen that the inhibitory effect of [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate on PR8 influenza virus is dose-dependent, and the inhibitory effect on the virus is better as the drug concentration increases. In addition, the results of viral nucleic acid detection in the culture supernatant treated with different concentrations of [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate after A549 cells were infected with influenza virus are shown in Table 2. The results in Table 2 also show that [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate at a concentration of 10μM-40μM has a significant inhibitory effect on the proliferation of PR8 influenza virus.

[0093] Table 2 Effects of different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of PR8 influenza virus

[0094]

[0095] Example 3: Inhibitory effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on influenza A virus at different time points

[0096] The present invention uses Western Blots and the number of viral nucleic acid copies in the culture supernatant to detect the effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of influenza A virus (PR8) at the cellular level, and the specific steps are as follows:

[0097] 1. Cells treated with [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate and infected with influenza A virus (PR8)

[0098] 1) A549 cells with good growth status were digested and subcultured, and the cell density was adjusted to 1×10 5 / mL, 1mL per well was inoculated in a 12-well plate to grow into a monolayer.

[0099] 2) A 40 μM solution of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution was added to set up a drug-free control for the DMSO group.

[0100] 3) After being treated with the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution for 24 h, the cells were infected with PR8 influenza virus and incubated at MOI = 0.05 for 1 h. The virus solution was discarded and the cells were continued to be cultured with the above-mentioned DMEM / F12 cell growth medium containing 40 μM [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate.

[0101] 4) Supernatants and cell lysates were collected 12 hours, 24 hours, and 36 hours after virus infection, and influenza virus NP protein in the lysates was detected by Western Blots, and the virus titer in the supernatant was detected by fluorescence quantitative PCR.

[0102] The steps of Western Blots detection of influenza virus NP protein in the lysate are the same as those in Example 2.

[0103] The steps of detecting the virus titer in the supernatant by fluorescence quantitative PCR are the same as those in Example 3.

[0104] 2. Western Blots to detect the proliferation of influenza A virus PR8 on cells at different time points

[0105] The cell lysate infected with influenza virus was subjected to Western Blots experiment to detect the effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of influenza A virus PR8. The specific steps are as follows:

[0106] 1) Add 5x protein loading to the virus-infected cell lysate collected above, boil in boiling water for 10 min, and centrifuge briefly for later use.

[0107] 2) SDS-PAGE electrophoresis: prepare 10% polyamide gel for separation gel, apply constant voltage of 80V for 30min to the concentrated gel and 120V for 1.5h to the separation gel.

[0108] 3) Transfer: When transferring, pre-cool the transfer solution in advance, put the PAGE gel after electrophoresis into the transfer tank, and transfer the membrane at a constant voltage of 100V for 1 hour.

[0109] 4) Blocking: After the transfer is completed, take out the NC membrane and block it with blocking solution for 1 hour.

[0110] 5) After the primary and secondary antibody incubation is completed, color development is performed: Thermo's ECL color development kit is used for color development.

[0111] 3. Fluorescence quantitative PCR was used to determine the nucleic acid copy number of influenza A virus after treatment with [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate for different time periods.

[0112] The supernatant of the A549 cells infected with influenza virus was used to quantitatively detect the number of viral copies in the supernatant by fluorescence, and the specific steps are as follows:

[0113] 1) 100 μL of supernatant was taken and viral RNA was extracted using a viral nucleic acid extraction kit produced by Magen. The steps of detecting the viral nucleic acid copy number by fluorescent quantitative PCR were the same as those in Example 3.

[0114] 2) Convert the test results into copy numbers according to the instructions and calculate the virus inhibition rate.

[0115] Test results:

[0116] The results are as follows Figure 3 As shown in the Western Blots results, [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate significantly inhibited the replication of PR8 influenza virus. After virus infection, the gray value of viral NP protein in the cell fluid treated with [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate at a concentration of 40 μM was significantly lower than that of the DMSO control group without drug addition at 12 hours, 24 hours and 36 hours. In addition, the results of viral nucleic acid detection in the supernatant are shown in Table 3.

[0117] Table 3 Effect of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on the proliferation of PR8 influenza virus at different time points

[0118]

[0119] The results in Table 3 also show that [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate has a significant inhibitory effect on the proliferation of PR8 influenza virus.

[0120] Example 4: [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate promotes cell autophagy

[0121] 1. Western Blots to detect the effect of small molecule compound [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate on cell autophagy:

[0122] In the present invention, Jurkat cells were planted in a 12-well plate, and then different concentrations of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution were added. After incubation for 24 hours, the cell lysate was collected and the autophagy marker p62 (SQSTM1) was detected by Western Blots experiment. The specific steps are as follows:

[0123] 1) Add 5x protein loading to the virus-infected cell lysate collected above, boil in boiling water for 10 min, and centrifuge briefly for later use.

[0124] 2) SDS-PAGE electrophoresis: prepare 10% polyamide gel for separation gel, apply constant voltage of 80V for 30min to the concentrated gel and 120V for 1.5h to the separation gel.

[0125] 3) Transfer: When transferring, pre-cool the transfer solution in advance, put the PAGE gel after electrophoresis into the transfer tank, and transfer the membrane at a constant voltage of 100V for 1 hour.

[0126] 4) Blocking: After the transfer is completed, take out the NC membrane and block it with blocking solution for 1 hour.

[0127] 5) After the primary and secondary antibody incubation is completed, color development is performed: Thermo's ECL color development kit is used for color development.

[0128] Test results:

[0129] The results are as follows Figure 4 Western Blots results show that [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate treatment can significantly promote the degradation of the autophagy marker p62 protein. As the concentration of [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate increases, the p62 protein gradually decreases. This suggests that [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate promotes cell autophagy.

[0130] 2. Laser confocal experiment to observe the formation of GFP-LC3 spots by the small molecule compound [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate:

[0131] The present invention plants A549 cells in a confocal culture dish, transfects GFP-LC3 plasmid after the cells adhere to the wall, adds 40 μM [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate drug solution or an equal volume of DMSO control 24 hours later, and observes the effect of the small molecule compound [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate on the formation of GFP-LC3 spots by laser confocal microscopy 24 hours later. The specific steps are as follows:

[0132] 1) Plate A549 cells onto a confocal experiment culture dish and wait for the cells to adhere to the wall overnight. Overnight culture refers to a culture time of ≥12 hours.

[0133] 2) Each well was transfected with 1 μg of GFP-LC3 plasmid, and 40 μM [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate drug solution or an equal volume of DMSO control was added 24 hours after transfection.

[0134] 3) After 24 hours, the culture supernatant was removed and paraformaldehyde cell fixative was added for 10 minutes, followed by addition of cell permeabilization solution containing 0.1% Triton X-100 for 15 minutes.

[0135] 4) Wash with PBS three times, add DAPI staining solution, incubate for 10 minutes, wash one side with PBS, and then observe GFP-LC3 spots using a confocal microscope.

[0136] Test results:

[0137] The results are as follows Figure 5 As shown in the results, [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate compound treatment significantly increased GFP-LC3 spot formation.

[0138] From the above experimental results, it can be seen that [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate has a significant inhibitory effect on influenza virus replication and has great potential value in preventing or treating influenza virus infection. At the same time, we also found that the small molecule [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate has a significant effect on promoting cell autophagy. In view of the close correlation between autophagy and influenza virus replication, we speculate that the effect of [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate on influenza virus replication is closely related to cell autophagy. In addition, changes in cell autophagy activity are also related to tumors, aging, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. The small molecule [(3-aminopyridin-2-yl) methyleneamino]-2-nitrobenzoate has the same research value in the above diseases.

[0139] The invention provides the use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of drugs for inhibiting influenza A virus, and provides a new method for treating or preventing influenza A virus infection.

[0140] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0141] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the preparation of a product for inhibiting influenza virus, characterized in that: The structural formula of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate is as follows:

2. The use according to claim 1, characterized in that: The influenza virus includes the A / PR / 8 / 34 (H1N1) strain.

3. Use of [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate according to claim 1 in the preparation of a medicament for treating or preventing influenza A virus infection.

4. The use according to claim 1 or 3, characterized in that: The medicine uses the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate as an active ingredient and is supplemented with a pharmaceutically acceptable carrier.

5. The use according to claim 4, characterized in that: The carrier includes any one or more of glycerol, lecithin and cholesterol.

6. The use according to claim 4, characterized in that: The effective concentration of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the drug is 10 μM to 40 μM.

7. The use according to claim 4, characterized in that: The medicine includes oral dosage form, injection dosage form and inhalation dosage form.

8. The use according to claim 7, characterized in that: The medicine is in the form of solution, tablet or granule.

9. The use according to claim 8, characterized in that: The drug is a solution, and the solvent in the solution is DMSO; The effective concentration of the [(3-aminopyridin-2-yl)methyleneamino]-2-nitrobenzoate in the drug is 10 μM to 40 μM.

Citation Information

Patent Citations

  • Pyridino-pyrazolon derivative and application thereof medicine against anti-influenza-a virus

    CN106432230A

  • Application of effective inhibitor of III-type phosphatidylinositol phosphate kinase in preparing drug for treating or preventing influenza virus infection

    CN109453174A

  • Application of 3-indoleacetonitrile to preparation of medicine for inhibiting novel coronavirus SARS-CoV-2

    CN112891343A

  • Methods for Inhibiting Virus Replication

    US20140121237A1